CA2614327A1 - Use of thiazole derivatives and analogues in disorders caused by free fatty acids - Google Patents

Use of thiazole derivatives and analogues in disorders caused by free fatty acids Download PDF

Info

Publication number
CA2614327A1
CA2614327A1 CA002614327A CA2614327A CA2614327A1 CA 2614327 A1 CA2614327 A1 CA 2614327A1 CA 002614327 A CA002614327 A CA 002614327A CA 2614327 A CA2614327 A CA 2614327A CA 2614327 A1 CA2614327 A1 CA 2614327A1
Authority
CA
Canada
Prior art keywords
compound
formula
benzyl
title compound
thiazolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002614327A
Other languages
English (en)
French (fr)
Inventor
Bjorn Eriksson
Guido Kurz
Christian Hedberg
Jacob Westman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagenon AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2614327A1 publication Critical patent/CA2614327A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002614327A 2005-07-21 2006-07-21 Use of thiazole derivatives and analogues in disorders caused by free fatty acids Abandoned CA2614327A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US59562005P 2005-07-21 2005-07-21
SE0501721 2005-07-21
US60/595,620 2005-07-21
SE0501721-5 2005-07-21
US74442206P 2006-04-07 2006-04-07
US60/744,422 2006-04-07
PCT/GB2006/002743 WO2007010281A2 (en) 2005-07-21 2006-07-21 Use of thiazole derivatives and analogues in disorders caused by free fatty acids

Publications (1)

Publication Number Publication Date
CA2614327A1 true CA2614327A1 (en) 2007-01-25

Family

ID=37669179

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002614327A Abandoned CA2614327A1 (en) 2005-07-21 2006-07-21 Use of thiazole derivatives and analogues in disorders caused by free fatty acids
CA002615752A Abandoned CA2615752A1 (en) 2005-07-21 2006-07-21 Use of thiazole derivatives and analogues in the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002615752A Abandoned CA2615752A1 (en) 2005-07-21 2006-07-21 Use of thiazole derivatives and analogues in the treatment of cancer

Country Status (10)

Country Link
US (2) US20090156644A1 (enExample)
EP (2) EP1906956A2 (enExample)
JP (2) JP2009501776A (enExample)
KR (2) KR20080032096A (enExample)
AU (2) AU2006271383A1 (enExample)
CA (2) CA2614327A1 (enExample)
EA (2) EA200800302A1 (enExample)
IL (2) IL188031A0 (enExample)
NO (2) NO20076333L (enExample)
WO (2) WO2007010281A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005024012A1 (de) * 2005-05-20 2006-11-23 Grünenthal GmbH Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
WO2008090327A1 (en) * 2007-01-22 2008-07-31 Betagenon Ab New combination for use in the treatment of cancer
EP2136809A4 (en) * 2007-03-20 2012-01-04 Curis Inc INHIBITORS OF RAF KINASE CONTAINING A ZINC BINDING FRAGMENT
CN101274918A (zh) * 2007-03-30 2008-10-01 中国科学院上海药物研究所 一类取代五元杂环化合物,其制备方法和医学用途
AR067770A1 (es) * 2007-08-03 2009-10-21 Betagenon Ab Derivados de tiazol y ditiazol para el tratamiento de diabetes
AU2008310097B2 (en) 2007-10-09 2013-05-16 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
EP2217235A4 (en) * 2007-11-15 2011-01-12 Musc Found For Res Dev INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
KR100998572B1 (ko) * 2007-12-14 2010-12-07 한국생명공학연구원 단백질 포스파타제의 활성을 억제하는 페닐아미노티아졸론유도체 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 암 예방 및 치료용 조성물
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
ES2567753T3 (es) 2009-07-08 2016-04-26 Baltic Bio Ab Derivados de 1,2,4-tiazolidin-3-ona y su uso en el tratamiento del cáncer
US9221773B2 (en) * 2009-12-22 2015-12-29 The Translational Genomics Research Institute Benzamide derivatives
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
WO2013049119A1 (en) * 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Selective nr2b antagonists
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
CN104059060B (zh) * 2014-05-30 2017-08-01 西安交通大学 一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用
EP4013744A1 (de) * 2019-08-15 2022-06-22 Bayer Aktiengesellschaft Verfahren zur herstellung von 2-(phenylimino)-3-alkyl-1,3-thiazolidin-4-onen
WO2023111996A1 (en) 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3345374A (en) * 1962-09-04 1967-10-03 Bayer Ag Certain oxathiazole and dithiazole derivatives
US3671537A (en) * 1969-06-05 1972-06-20 Gyogyszerkutato Intezet Certain 3-(2,6-dichlorophenyl)-2-iminothiazolidines
US4103018A (en) * 1976-10-12 1978-07-25 Schering Corporation 2-[4-(Polyhalo-2-hydroxy-2-propyl)anilino]-2-oxazolin-4-ones and thiazolin-4-ones corresponding thereto
HU191408B (en) * 1984-04-25 1987-02-27 Egis Gyogyszergyar,Hu Process for preparing new imino-thiazolidine derivatives
DD246541A1 (de) * 1986-01-27 1987-06-10 Univ Halle Wittenberg Verfahren zur herstellung von 5-arylidenthiazolidin-4-onen
DD270072A1 (de) * 1988-03-14 1989-07-19 Univ Halle Wittenberg Verfahren zur herstellung von 5-aryliden- hoch 2-thiazolin-4-onen
US6353006B1 (en) * 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
AU2003282980A1 (en) * 2002-10-23 2004-05-13 Beyond Genomics, Inc. 4-alkenylthiazoles comprising epoxide functionality, and methods of use thereof
WO2005082363A1 (en) * 2004-02-20 2005-09-09 Board Of Regents, The University Of Texas System Thiazolone compounds for treatment of cancer
EP1747218A2 (en) * 2004-04-30 2007-01-31 Schering Corporation Neuropeptide receptor modulators
AU2005259512A1 (en) * 2004-07-01 2006-01-12 F. Hoffmann-La Roche Ag Thiazolinone unsubstituted quinolines
EP1776112A4 (en) * 2004-08-10 2009-11-25 Exelixis Inc HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS
RU2405782C2 (ru) * 2004-10-14 2010-12-10 Ф.Хоффманн-Ля Рош Аг Хиназолинилметилентиазолиноны в качестве cdk-1 ингибиторов
CN100525929C (zh) * 2005-04-20 2009-08-12 郭文礼 喷水枪出水控制装置
JP2009500351A (ja) * 2005-07-04 2009-01-08 ドクター レディズ ラボラトリーズ リミテッド Ａｍｐｋアクチベータとしてのチアゾール誘導体

Also Published As

Publication number Publication date
JP2009501775A (ja) 2009-01-22
EA200800303A1 (ru) 2008-10-30
AU2006271383A1 (en) 2007-01-25
JP2009501776A (ja) 2009-01-22
NO20076333L (no) 2008-04-01
WO2007010281A2 (en) 2007-01-25
EA200800302A1 (ru) 2008-08-29
WO2007010273A2 (en) 2007-01-25
CA2615752A1 (en) 2007-01-25
EP1906956A2 (en) 2008-04-09
IL188031A0 (en) 2011-08-01
NO20076420L (no) 2008-04-09
KR20080034436A (ko) 2008-04-21
US20090136472A1 (en) 2009-05-28
EP1906955A2 (en) 2008-04-09
AU2006271375A2 (en) 2007-01-25
IL188163A0 (en) 2008-03-20
AU2006271375A1 (en) 2007-01-25
WO2007010281A3 (en) 2007-06-07
US20090156644A1 (en) 2009-06-18
WO2007010273A3 (en) 2007-05-10
KR20080032096A (ko) 2008-04-14

Similar Documents

Publication Publication Date Title
CA2614327A1 (en) Use of thiazole derivatives and analogues in disorders caused by free fatty acids
US8524756B2 (en) Compounds for inflammation and immune-related uses
CN102596923B (zh) 1,2,4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途
WO2008090356A1 (en) Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
JP2010512410A (ja) 心筋虚血を予防または処置するための方法
WO2010027005A1 (ja) 置換アミン誘導体及びこれを有効成分とする医薬組成物
WO2019162702A1 (en) Triazine derivatives for treating diseases relating to neurotrophins
KR20070050932A (ko) Ｖａｐ―１ 억제 활성을 가지는 티아졸 유도체
EP2793883A1 (en) Trpm8 antagonists
WO2008090327A1 (en) New combination for use in the treatment of cancer
WO2008065409A2 (en) Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
JP6197971B1 (ja) Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
CN101237866A (zh) 噻唑类衍生物和类似物在游离脂肪酸引起的疾病中的应用
TWI438206B (zh) 〔１，２，４〕噻二１，１二氧化物化合物
JP4661595B2 (ja) フェニル酢酸誘導体、その製造方法および用途
CN101784285B (zh) 用于与低氧或局部缺血有关的眼科疾病的组合物
MX2008000973A (en) Use of thiazole derivatives and analogues in disorders caused by free fatty acids
BRPI0613624A2 (pt) uso de um composto ou um sal ou solvato farmaceuticamente aceitável, ou um derivado farmaceuticamente funcional do mesmo, composto ou um sal ou solvato farmaceuticamente aceitável, ou um derivado funcional do mesmo, formulação farmacêutica, produto combinado, e, métodos de varredura para inibidores de proliferação celular induzida por ácido graxo livre, e para co-estimuladores de proliferação celular induzida por ácido graxo livre
US7300949B2 (en) Thiazolopyrazoles and methods of their use
WO2006095822A1 (ja) スルホンアミド化合物およびその医薬
MX2008000972A (en) Use of thiazole derivatives and analogues in the treatment of cancer
AU2014297912A1 (en) Novel indazole compounds and a process for the preparation thereof
KR20030046470A (ko) 기도 점액 분비 억제제

Legal Events

Date Code Title Description
FZDE Discontinued